Oncolytic group B adenovirus expressing a stroma-targeted bispecific t-cell engager
US12049513B2 · kind B2 · utility
0Cited by
17References
26Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Aug 29, 2017 |
| Grant date | Jul 30, 2024 |
| Priority date | — |
| Expiry date | Jul 10, 2040 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2840/44
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A modified adenovirus, in particular Enadenotucirev (EnAd), armed with a bispecific T cell activator comprising at least two binding domains, wherein at least one of the domains is specific for a surface antigen on a T-cell of interest. Also provided are a composition, such as a pharmaceutical formulation comprising the virus, use of the virus and virus formulations for treatment, such as in the treatment of cancer. The disclosure also extends to processes for preparing the virus.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.